Xintela strengthens management team with Peter Ekolind as COO & VP Commercial Manufacturing

With this recruitment, Xintela reinforces its focus on the company’s GMP manufacturing facility, a strategic asset for the commercial production of cell therapy products as well as for the supply of stem cells and stem cell-related products to other companies in the field. This initiative broadens the company’s revenue base and, over time, establishes the GMP facility as a sustainable source of income for Xintela. Peter started his position on August 18, 2025.

“We are very pleased to welcome Peter Ekolind back to Xintela. His broad experience from both our own operations and from leading roles in other companies within advanced therapies (ATMP) strengthens our management team and provides us with the right conditions to further develop our GMP facility into a profit-making business,” says Evy Lundgren-Åkerlund, CEO of Xintela.